AIA-PACK Series

Prostate Health

Screening with Meaning

In the US, prostate cancer is the most common cancer in men and the second leading cause of cancer death. It is estimated that 1 in 6 men will develop prostate cancer in their lifetime. While the disease progression may be slow and asymptomatic, screening and early detection is key to reducing mortality rates[1].

The Prostate Specific Antigen (PSA) test is the first FDA-approved blood test for screening of prostate cancer when combined with a digital rectal examination. It is also used for disease management through surveillance, assessment of response to therapy and monitoring of recurrence in follow up patients. This has led to the reduction of prostate cancer deaths in the US and Europe[2].

Using the right assay is important for gathering meaningful results for early diagnosis and monitoring with confidence. Tosoh's PSA assay is based on the classical Hybritech® equimolar assay that measures PSA with better diagnostic accuracy compared to nonequimolar PSA tests. Our offering delivers the quality, precision and accuracy that you can rely on.

TOSOH BIOSCIENCE
www.tosohbioscience.us

TOSOH

Universal Reagent

Tosoh's AIA-PACK test cup format works with every Tosoh automated immunoassay system allowing for a seamless transition from one system to the other, ensuring consistent results in an efficient and economical process.

Save Time and Money

Tosoh's AIA-PACK test cups are single, unitized cups that use a dry reagent format that ensures calibration stability of up to 90 days.

No Contamination, More Traceability

Because there is no transfer of reagents the risk of contamination is eliminated. The unique bichromatic fluorescence kinetic measurement ensures a high analytical and functional sensitivity for all assays. AIA-PACK test cups and trays are labelled with the assay code and lot number for automated scheduling and inventory.

Tosoh's Equimolar PSA Test

- Based on classical Hybritech® equimolar monoclonal antibodies[3], the first FDA-approved assay for prostate cancer detection and monitoring and the gold standard upon which the FDA-approved clinical cut-off is based.
- Equimolar PSA assay that shows better diagnostic sensitivity and specificity compared to nonequimolar PSA assays[4,5]
- Accurate assay with better discrimination between benign prostatic hyperplasia and prostate cancer[4,5]
- Avoid unnecessary biopsies[4,5]



Choose Wisely. Choose Tosoh.

- Accurate & precise
- Specific & sensitive
- Correlation with gold standard methods
- No Biotin Interference — Biotin-free immunoassays
- Extensive test menu
- Up to 90 day calibration stability
- 10 min incubation times
- Automated workflows

Available for Labs and Workloads of All Sizes

AIA-360

AIA-900
Benchtop

AIA-900
with 9 Tray Sorter
Also available with 19 tray sorter option and as Loader model

AIA-2000

Tosoh products are for Prescription use only as In-Vitro Diagnostics

Tosoh Bioscience, Inc.
6000 Shoreline Court, Suite 101
South San Francisco, CA 94080
Tel: (800) 248-6764
Fax: (650) 615-0415
www.tosohbioscience.us

References

1. Esserman, L., Shieh, Y. & Thompson, I. Rethinking screening for breast cancer and prostate cancer. JAMA 302, 1685–1692 (2009).
2. Schröder, M.D. et al; N Engl J Med 2009;360:1320–8.
3. Prestigiacomo, et al. A Comparison of 4 Ultrasensitive Prostate Specific Antigen Assays for Early Detection of Residual Cancer after Radical Prostatectomy. The Journal of Urology 1994; 152: 1515-1519.
4. Andrew W. Roddam, et al. Assessing the Clinical Impact of Prostate-Specific Antigen Assay Variability and Nonequimolarity: A Simulation Study Based on the Population of the United Kingdom Clinical Chemistry. Vol. 50, Issue 6 June, 2004
5. Onur R, et al. Increased discrimination between benign prostatic hyperplasia and prostate cancer with equimolar

AIA-TUM-SS02 Rev. 1/2019